KIMBERLY MILLS: Open Payments
NPI 1841215464 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$882 in 51 payments from 12 companies in 2025. Trend: 2023 $1,007 · 2024 $529 · 2025 $882
Food & beverage: $882
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 18 | $279 |
| ABBVIE INC. | 12 | $155 |
| UCB, Inc. | 4 | $101 |
| Janssen Biotech, Inc. | 3 | $58 |
| LEO Pharma Inc. | 2 | $50 |
| Regeneron Healthcare Solutions, Inc. | 2 | $50 |
| Amgen Inc. | 2 | $38 |
| Galderma Laboratories, L.P. | 2 | $34 |
| Paratek Pharmaceuticals, Inc. | 2 | $31 |
| Lilly USA, LLC | 2 | $30 |
Products named: COSENTYX, SKYRIZI, Bimzelx, DUPIXENT, TREMFYA, OTEZLA, NEMLUVIO, NUZYRA.
Industry payments across AL — which companies pay providers there.
